A new presentation of Fresenius Kabi Heparin is now available in the company’s Simplist^® ready-to-administer prefilled syringe, expanding the company's Heparin portfolio.

Fresenius Kabi has completed the expansion of its plant in Aquiraz, Brazil, increasing the facility’s capacity for parenteral nutrition production by around 30 percent. The company expects to hire about 50 new employees to bring the plant’s workforce to about 850. Fresenius Kabi, which has been active in Brazil for more than 40 years, invested some €20 million in the expansion and modernization of the Aquiraz plant.

Fresenius Kabi has completed the expansion of its plant in Aquiraz, Brazil, increasing the facility’s capacity for parenteral nutrition production by around 30 percent. The company expects to hire about 50 new employees to bring the plant’s workforce to about 850. Fresenius Kabi, which has been active in Brazil for more than 40 years, invested some €20 million in the expansion and modernization of the Aquiraz plant.

Fulvestrant Injection is now available in the United States in the company’s ready-to-administer prefilled syringes and is the latest addition to Fresenius Kabi’s broad oncology portfolio. The product is the only room temperature stable Fulvestrant Injection currently available in the U.S.

Fresenius Kabi has opened a new research and development center for biosimilars in Eysins, in the Swiss canton of Vaud. The facility, in which the company invested about €15 million, will strengthen Fresenius Kabi’s capability to develop new biosimilars, particularly in the areas of autoimmune diseases and oncology. A biosimilar is a drug that is “similar” to another, already approved biologic drug. More than 100 employees representing over 20 nationalities work at the Eysins site, and the company plans to expand the workforce in the near future.

Fresenius Kabi has opened a new research and development center for biosimilars in Eysins, in the Swiss canton of Vaud. The facility, in which the company invested about €15 million, will strengthen Fresenius Kabi’s capability to develop new biosimilars, particularly in the areas of autoimmune diseases and oncology. A biosimilar is a drug that is “similar” to another, already approved biologic drug. More than 100 employees representing over 20 nationalities work at the Eysins site, and the company plans to expand the workforce in the near future.

Phenylephrine Hydrochloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.